Paradigm has results from its Phase 2 hay fever trial pending in six weeks.
ACCESS THE FULL PRESENTATION HERE
View full PAR profile View Profile
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
The health and wellbeing group, which has a broad product portfolio, had an eventful 2017,